Mohammad Mahdi Parvizi

Mohammad Mahdi Parvizi

Auto-generated profile, based on publicly available information

Mohammad Mahdi Parvizi

Molecular Dermatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2020 in Health and Quality of Life Outcomes
Verified
Journal Article
Open access
PDF file
NHNasrin Hamidizadeh
Nasrin Hamidizadeh
SRSara Ranjbar
Sara Ranjbar
AGAhmad Ghanizadeh
Ahmad Ghanizadeh
MPMohammad Mahdi Parvizi
Mohammad Mahdi Parvizi
PJPeyman Jafari
Peyman Jafari
FHFarhad Handjani
Farhad Handjani
Introduction: Vitiligo is caused by partial or complete destruction of melanocytes in the affected skin area and influences the patient’s quality of life. Besides physical involvement, vitiligo patients experience a high level of stress. Depression and Anxiety are common psychiatric disorders in vitiligo patients. Aim: This study, as the first study, evaluates hopelessness, anxiety, depression and general health of vitiligo patients in comparison with normal controls in an Iranian population. Method: Hundred patients with vitiligo and hundred healthy controls were examined. General health, depression, hopelessness and anxiety were evaluated based on general health questionnaire. Anxiety, depression and hopelessness levels were analyzed using Chi–Square, and the mean value of general health was evaluated through t-test. Results: The results showed that anxiety and hopelessness levels were significantly higher in vitiligo patients than those who are in healthy controls. This significant difference refers to high levels of anxiety and hopelessness among women with vitiligo. It was also found that the single patients were more anxious, hopeless and depressive, while the married patients were only more anxious and hopeless than those who are in the control group, respectively. General health of patients was significantly worse than in healthy controls. The low level of general health in patients was related to poorer level of general health among women with vitiligo. Conclusion: It seems that women with vitiligo are more mentally stressed than men with vitiligo. Both singles and married vitiligo patients suffer from anxiety and hopelessness.

5 October 2017 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
MPMohammad Mahdi Parvizi
Mohammad Mahdi Parvizi
FHFarhad Handjani
Farhad Handjani
MMMahmoodreza Moein
Mahmoodreza Moein
GHGholamreza Hatam
Gholamreza Hatam
MNMajid Nimrouzi
Majid Nimrouzi
MZMohammad Mehdi Zarshenas
Mohammad Mehdi Zarshenas
Cutaneous leishmaniasis is one of the highly prevalent endemic diseases in the Middle East and North Africa. Many treatment modalities have been recommended for this condition but success rates remain limited. Herbal remedies have also been used for treatment but evidence-based clinical trials with these products are sparse. In-vitro and in-vivo studies have shown the anti-leishmanial and curative effects of extract of fruits and leaves of Juniperus excelsa (J. excelsa). The aim of this study was to determine the efficacy of topical J. excelsa M. Bieb extract as an adjuvant to cryotherapy for the treatment of human CL. This study was designed as a two-arm triple-blind randomized placebo-controlled clinical trial using a parallel design. Seventy-two patients with clinical diagnosis of CL confirmed by leishmania smears were allocated to receive either a topical formulation of leaf of J. excelsa extract (group A) or placebo (group B) for 3 months. Both groups received cryotherapy as baseline standard treatment. Patients were evaluated before and weekly after the intervention was initiated until complete cure. Overall, 82% of patients in group A, experienced complete cure and 9% of them had partial cure. On the other hand, 34% in group B reported complete cure, while 14% of them had partial cure at the end of treatment protocol with a significant difference between the two groups (P< 0.001). The mean duration to healing of the lesions in patients who received J. excelsa extract was statistically significantly shorter than the placebo group (p = 0.04). No significant side effect was seen in the J. excelsa extract group except for mild to moderate local irritation after a few weeks in a few numbers of patients. The results of this study showed that topical J. excelsa extract can be used as an adjuvant treatment modality in addition to cryotherapy for accelerating the time to cure in addition to increasing the complete cure rate in CL. ClinicalTrials.gov IRCT2015082523753N1 Many people were afflicted in the world by cutaneous leishmaniasis (CL). The pathogen in this disease is an intracellular parasite. In 2007, The World Health Organization, defined leishmaniasis as a neglected disease. Many treatment modalities have been recommended for cutaneous leishmaniasis, but success rates remain limited. Experimental studies have shown the anti-leishmanial and curative effects of extract of fruits and leaves of Juniperus excelsa (J. excelsa), but there are no documentation in this regard in humans. This is the first randomized controlled clinical trial which evaluated the efficacy of the leaf extract of J. excelsa M. Bieb on human CL. According to the results of this present study, topical J. excelsa M. Bieb hydroalcoholic extract could be a good choice for treatment of CL in conjunction with cryotherapy. Using this extract along with cryotherapy can decrease the duration of CL treatment and also increase the success rate of CL treatment without any significant adverse effect.

2 September 2020 in Dermatologic Therapy
Verified
Journal Article
Closed access
PDF file
SASoheila Alyasin
Soheila Alyasin
SNSeyed Hesamedin Nabavizadeh
Seyed Hesamedin Nabavizadeh
HEHossein Esmaeilzadeh
Hossein Esmaeilzadeh
SHSeyed Taghi Heydari
Seyed Taghi Heydari
SMSeyed Hamdollah Mosavat
Seyed Hamdollah Mosavat
Mohammad Hashem HashempurMohammad Hashem Hashempur
Mohammad Hashem Hashempur

26 August 2021 in International Journal of Women's Dermatology
Verified
Journal Article
Open access
FCFatemeh Chogani
Fatemeh Chogani
MPMohammad Mahdi Parvizi
Mohammad Mahdi Parvizi
DMDedee F. Murrell
Dedee F. Murrell
FHFarhad Handjani
Farhad Handjani
Epidermolysis bullosa (EB) is an uncommon group of inherited disorders characterized by skin blistering after friction or mechanical trauma. EB affects patients and their families physically, socially, and emotionally. This study aimed to assess the family quality of life of these patients using the Family Dermatology Life Quality Index (FDLQI) questionnaire. In this cross-sectional study, we enrolled caregivers of patients with EB registered at the Molecular Dermatology Research Center, affiliated with Shiraz University of Medical Sciences, up to 2020. Participants filled out a demographic data collection form and the FDLQI questionnaire. The data were analyzed using SPSS software, version 22. Overall, 80 participants, consisting of 65 mothers (81.2%) and 15 fathers (18.7%) as primary caregivers, were enrolled in this study. The average FDLQI score was 19.88 ± 4.71. The FDLQI scores of caregivers of patients with EB simplex was significantly lower than scores observed in those with other types of EB (p < .001). There was a significant positive association between the number of patients with EB in the family and FDLQI score (p = .049). FDLQI scores were lower in caregiving mothers who had a higher education (p < .001) and those who were employed (p < .001). Family quality of life is affected in patients with EB. Families with lower socioeconomic status and unemployed caregivers require special attention. More studies are needed to determine the parameters involved in the quality of life of patients with EB and their families.

13 May 2020 in Dermatologic Therapy
Verified
Journal Article
Closed access
PDF file
MPMohammad Mahdi Parvizi
Mohammad Mahdi Parvizi
FZFarzaneh Zare
Farzaneh Zare
FHFarhad Handjani
Farhad Handjani
MNMajid Nimrouzi
Majid Nimrouzi
MZMohammad Mehdi Zarshenas
Mohammad Mehdi Zarshenas

30 September 2022 in BMC Complementary Medicine and Therapies
Verified
Journal Article
Open access
PDF file
MPMohammad Mahdi Parvizi
Mohammad Mahdi Parvizi
SFSedigheh Forouhari
Sedigheh Forouhari
RSReza Shahriarirad
Reza Shahriarirad
SSSepehr Shahriarirad
Sepehr Shahriarirad
RBRyan Bradley
Ryan Bradley
LRLeila Roosta
Leila Roosta
Background: Complementary and Integrative Medicine (CIM) is often taken up by individuals seeking relief from different diseases. This study investigates the prevalence and associated factors of CIM use in patients with COVID-19.Methods: In this telephone-based, cross-sectional study, data on CIM usage were collected from COVID-19 patients from February till June 2020 in Fars province, Iran using a researcher-made checklist. Additionally, we asked about the patients’ attitudes toward these treatments.Results: Out of 453 patients diagnosed with COVID-19, 400 (88.30%) responded to our calls and agreed to participate in the study. Among them, 276 patients reported using CIM to treat COVID-19 [prevalence: 69% (95% CI: 64.2 to 73.5)]. The most frequently used herbal medicine among COVID-19 patients was ginger (n = 273, 98.9%), thyme (n = 263, 95.3%), and black cumin (n = 205, 74.3%). Most of these patients were recommended to use herbal medicine by their families and friends (n = 96, 34.8%). Univariable logistic regression revealed that age under 50 years old, residency in urban areas (including the capital of the province and small cities), employment, academic education, and being an outpatient were statistically significant factors resulting in CIM usage. Multivariable logistic regression revealed that CIM use among outpatients was 3.65 times more than among inpatients. In addition, patients under 50 years old used CIM 85% more than older patients. Ultimately, only 9 (3.3%) patients consulted with their doctors regarding these medications. No side effects due to CIM use were reported.Conclusion: Many patients with COVID-19 used CIM, but few consulted with their physicians in this regard. Therefore, physicians should ask their patients about CIM usage, and patients should also report their use of CIM therapies during their medical visits. Furthermore, age and hospitalization status affected CIM use among patients with COVID-19.